Tadalafil and riociguat should not be used concomitantly under current U.S. labeling. CIALIS identifies guanylate cyclase stimulators such as riociguat as a formal contraindication because PDE5 inhibitors can potentiate their hypotensive effects.
The interaction occurs because the two drugs influence different points of the same broader cyclic GMP pathway. Riociguat increases cGMP generation by stimulating soluble guanylate cyclase, while tadalafil inhibits PDE5-mediated cGMP breakdown; overlapping effects can intensify vasodilation and lower systemic blood pressure.
This page focuses specifically on that GC-stimulator interaction rather than repeating the broad tadalafil contraindication list or the master interaction framework. It also distinguishes tadalafil-specific label instructions from clinical evidence involving other PDE5 inhibitors so that class-level evidence is not presented as if it were a direct tadalafil-riociguat trial.
The regulatory conclusion is straightforward: tadalafil and riociguat belong to a contraindicated interaction category. This is stronger than a recommendation to monitor blood pressure, lower a routine dose or simply separate simultaneous administration.
Both U.S. tadalafil labeling and riociguat labeling identify the combination through the PDE5 inhibitor–soluble guanylate cyclase interaction. The principal concern is excessive pharmacodynamic blood-pressure lowering.
The key distinction is that this interaction involves two different drug targets acting on the same signaling system rather than one drug raising the plasma concentration of the other.
| Question | Current-label answer |
|---|---|
| Tadalafil + riociguat | Contraindicated |
| Tadalafil drug class | PDE5 inhibitor |
| Riociguat drug class | Soluble guanylate cyclase stimulator |
| Main interaction type | Pharmacodynamic |
| Principal concern | Potentiated hypotension |
Tadalafil and riociguat do not act on the same protein. Tadalafil inhibits phosphodiesterase type 5, while riociguat stimulates soluble guanylate cyclase, an enzyme that generates cGMP in response to nitric oxide signaling.
Those different targets converge on cGMP. One drug reduces cGMP degradation and the other increases its production, creating the potential for greater downstream smooth-muscle relaxation and vasodilation than would be expected from either mechanism alone.
That pathway overlap explains why the combination is treated more seriously than many ordinary blood-pressure interactions.
| Feature | Tadalafil | Riociguat |
|---|---|---|
| Primary target | PDE5 | Soluble guanylate cyclase (sGC) |
| Primary action | Inhibits cGMP degradation | Stimulates cGMP generation |
| Effect on cGMP signaling | Allows cGMP to persist | Increases cGMP production |
| Vascular consequence | Supports smooth-muscle relaxation | Promotes vasodilation through increased cGMP |
| Combined concern | Potentially excessive cGMP-mediated vasodilation | Potentially excessive cGMP-mediated vasodilation |
PDE5 normally degrades cGMP. By inhibiting PDE5, tadalafil increases the amount and persistence of cGMP generated in tissues where this pathway is active.
In erectile tissue, tadalafil's effect depends on nitric oxide release associated with sexual stimulation, but PDE5 and cGMP signaling are not confined to the penis. PDE5 activity is also relevant in pulmonary and systemic vascular smooth muscle.
For the riociguat interaction, the important concept is therefore not erectile response itself but the vascular consequence of preventing cGMP breakdown while another drug simultaneously drives cGMP generation.
| Tadalafil pathway step | Effect |
|---|---|
| PDE5 activity | Normally contributes to cGMP degradation |
| Tadalafil inhibits PDE5 | cGMP breakdown is reduced |
| Result | cGMP signaling can persist or increase |
| Interaction relevance | Greater potential for vasodilation when cGMP production is also strongly stimulated |
Current Adempas labeling describes riociguat as a soluble guanylate cyclase stimulator with a dual mode of action. It sensitizes sGC to endogenous nitric oxide by stabilizing NO-sGC binding and also directly stimulates sGC through a separate binding site independently of nitric oxide.
Both actions increase generation of cGMP. The downstream pharmacodynamic effect includes vasodilation and changes in hemodynamic variables such as systemic vascular resistance and blood pressure.
This is what distinguishes riociguat from an ordinary antihypertensive that lowers pressure through an unrelated pathway: its pharmacology directly overlaps with the signaling amplified by PDE5 inhibition.
| Riociguat action | Meaning |
|---|---|
| Sensitizes sGC to endogenous NO | Strengthens NO-dependent sGC signaling |
| Directly stimulates sGC | Can stimulate the enzyme independently of NO |
| Both mechanisms | Increase cGMP generation |
| Downstream effect | Vasodilation and hemodynamic change |
The interaction is best understood as simultaneous pressure on two sides of the same cGMP balance. Riociguat increases cGMP generation while tadalafil limits one of the principal pathways responsible for cGMP degradation.
Higher cGMP signaling promotes relaxation of vascular smooth muscle. When the effects overlap, blood-pressure lowering can become greater than intended and may produce clinically significant hypotension.
Current CIALIS patient counseling therefore warns that concomitant GC-stimulator use may cause blood pressure to fall to an unsafe level.
| Mechanistic contribution | Direction |
|---|---|
| Riociguat | More cGMP generated |
| Tadalafil | Less cGMP degraded through PDE5 |
| Combined pathway effect | Greater cGMP signaling |
| Potential systemic result | Excessive vasodilation and hypotension |
The current U.S. CIALIS prescribing information places concomitant guanylate cyclase stimulators in the formal contraindications section. It instructs clinicians not to use CIALIS in patients using a GC stimulator such as riociguat.
The label explains the reason at a high level: PDE5 inhibitors, including tadalafil, may potentiate the hypotensive effects of GC stimulators. Patient counseling likewise identifies the combination as contraindicated rather than merely precautionary.
That wording is why this interaction belongs alongside the formal safety exclusions even though its molecular mechanism differs from the separate nitrate contraindication.
| CIALIS label point | Meaning |
|---|---|
| GC stimulator such as riociguat | Do not use concomitantly |
| Regulatory category | Contraindication |
| Mechanistic concern | Potentiation of hypotensive effects |
| Patient counseling | Combination may lower blood pressure to an unsafe level |
Current U.S. riociguat labeling approaches the same interaction from the opposite direction. It contraindicates concomitant administration with specific PDE5 inhibitors and explicitly names sildenafil, tadalafil and vardenafil as examples.
This reciprocal wording is useful because the contraindication is not inferred only from the tadalafil label. Both sides of the interaction identify PDE5 inhibitor plus riociguat therapy as an unacceptable concomitant combination.
The riociguat label also contains clinician-directed transition instructions intended to avoid overlap when treatment is being changed from one pathway-targeting therapy to another.
| Riociguat label category | Examples |
|---|---|
| Specific PDE5 inhibitors | Sildenafil, tadalafil, vardenafil |
| Concomitant use | Contraindicated |
| Reason stated in interaction section | Hypotension |
| Transitioning between therapies | Handled through separate label-specific timing instructions |
Current Adempas and current generic riociguat labeling include specific instructions for transitioning between PDE5 inhibitors and riociguat. For tadalafil, the label states that tadalafil should be discontinued at least 48 hours before riociguat is administered; when transitioning in the other direction, riociguat is discontinued at least 24 hours before a PDE5 inhibitor.
These instructions describe clinician-managed treatment transitions, not permission to use tadalafil and riociguat as a planned combination. The concomitant combination remains formally contraindicated.
Because pulmonary-hypertension therapy can involve complex hemodynamic decisions, these intervals should be understood as label context rather than converted into a self-directed switching schedule.
| Transition described in current riociguat labeling | Label interval | Interpretation |
|---|---|---|
| Tadalafil → riociguat | Discontinue tadalafil at least 48 hours before riociguat | Clinician-directed transition guidance |
| Riociguat → a PDE5 inhibitor | Discontinue riociguat at least 24 hours before the PDE5 inhibitor | Clinician-directed transition guidance |
| Tadalafil + riociguat together | No overlap intended | Contraindicated |
A common interpretation error is to see a transition interval and assume that the contraindication is merely a timing recommendation. The current riociguat label separates these concepts: concomitant PDE5-inhibitor therapy is contraindicated, while Section 2.6 provides instructions for switching therapies without intended overlap.
That distinction is particularly important because the interval after tadalafil is longer than the label's corresponding interval after sildenafil. Users should not generalize the timing of one PDE5 inhibitor to another or derive a personal schedule from drug half-lives.
The interaction page therefore preserves the label intervals as regulatory context while leaving treatment transitions to the prescribing team.
| Statement | Correct interpretation |
|---|---|
| There is a transition interval in the Adempas label | Yes |
| Therefore tadalafil and riociguat can routinely be combined | No |
| Every PDE5 inhibitor uses the same transition interval | No |
| Transitioning is distinct from concomitant treatment | Yes |
The regulatory contraindication explicitly includes tadalafil, but not every clinical trial behind the PDE5 inhibitor–riociguat safety concern tested tadalafil itself. That evidence distinction should be preserved.
The best-known controlled combination study, PATENT PLUS, evaluated riociguat added to sildenafil in patients with pulmonary arterial hypertension. It did not test tadalafil plus riociguat, so its outcomes should be described as class-relevant evidence rather than direct tadalafil-riociguat trial results.
Tadalafil-specific safety guidance nevertheless remains explicit in both tadalafil and riociguat labeling, including the named contraindication and tadalafil-specific transition interval.
| Evidence source | Tadalafil-specific? | What it supports |
|---|---|---|
| Current CIALIS contraindication | Yes | Do not use tadalafil with a GC stimulator such as riociguat |
| Current riociguat / Adempas contraindication | Yes | Tadalafil is explicitly named among contraindicated PDE5 inhibitors |
| Riociguat transition section | Yes | Tadalafil-specific transition timing |
| PATENT PLUS trial | No — sildenafil was the PDE5 inhibitor | Class-level clinical evidence about combining PDE5 inhibition with riociguat |
PATENT PLUS evaluated riociguat added to sildenafil in patients with pulmonary arterial hypertension. The randomized phase did not show a favorable effect on exploratory clinical outcomes, and the long-term extension produced concerning tolerability signals including frequent discontinuation due to hypotension.
The study therefore contributes clinical evidence that combining riociguat with established PDE5 inhibition does not provide a favorable benefit-risk profile. Importantly, it should not be rewritten as a tadalafil-riociguat trial because tadalafil was not the PDE5 inhibitor studied.
For this page, PATENT PLUS is useful as supporting class evidence rather than the basis for inventing tadalafil-specific event rates.
| PATENT PLUS feature | Interpretation |
|---|---|
| PDE5 inhibitor studied | Sildenafil |
| Added treatment | Riociguat |
| Favorable clinical benefit demonstrated | No |
| Long-term hypotension-related tolerability concern | Yes |
| Direct tadalafil-riociguat incidence data | No |
Tadalafil is contraindicated with both organic nitrates and riociguat, but the two interactions should not be treated as interchangeable. Organic nitrates increase nitric-oxide-related signaling, whereas riociguat directly stimulates soluble guanylate cyclase and also sensitizes it to endogenous nitric oxide.
The regulatory outcome is similar because both combinations can amplify cGMP-mediated vasodilation and hypotension, but the molecular starting points differ. That difference is why nitrate-specific timing-study evidence should remain on the separate tadalafil and nitrates page.
A shared contraindication outcome does not mean riociguat is simply another nitrate.
| Feature | Organic nitrate | Riociguat |
|---|---|---|
| Drug class | Nitrate / NO-donor therapy | Soluble guanylate cyclase stimulator |
| Primary pathway action | Increases NO-related signaling | Stimulates sGC and sensitizes it to NO |
| Interaction with tadalafil | Contraindicated | Contraindicated |
| Mechanism identical? | No | No |
The reason tadalafil and riociguat are contraindicated is not that riociguat is described as raising tadalafil AUC or Cmax. The clinically important interaction is pharmacodynamic: their actions converge on cGMP signaling and vascular tone.
This differs from drugs such as potent CYP3A4 inhibitors, which alter tadalafil metabolism and can increase systemic tadalafil exposure. Both categories matter clinically, but they should not be described with the same mechanism.
That separation is part of the broader classification explained on the tadalafil interactions hub.
| Interaction | Primary type | Main concern |
|---|---|---|
| Tadalafil + riociguat | Pharmacodynamic | Excessive hypotensive effect |
| Tadalafil + potent CYP3A4 inhibitor | Pharmacokinetic | Increased tadalafil exposure |
Riociguat itself lowers blood pressure, and its current labeling warns about symptomatic hypotension in susceptible patients. Patient information identifies symptoms such as dizziness, lightheadedness and fainting as signs that can occur when blood pressure becomes too low.
Adding PDE5 inhibition can increase the same hemodynamic direction of effect. That is why the combination is prohibited rather than managed as an ordinary expected side effect.
The contraindication is preventive: the goal is to avoid clinically important overlap rather than wait for hypotension symptoms to demonstrate that the combination is unsafe.
| Potential hypotension signal | Context |
|---|---|
| Dizziness | Possible symptom of low blood pressure |
| Lightheadedness | Possible symptom of low blood pressure |
| Fainting / syncope | More significant hypotensive symptom |
| Absence of symptoms during prior use | Does not remove the formal contraindication |
The tadalafil-riociguat interaction is particularly relevant because both drug classes appear in pulmonary-hypertension treatment contexts. Tadalafil is the active drug in Adcirca, which is labeled for pulmonary arterial hypertension, while riociguat is used in selected forms of pulmonary hypertension including PAH and chronic thromboembolic pulmonary hypertension.
Having therapeutic roles within the same disease area does not mean the drugs should be combined. Current riociguat labeling specifically contraindicates PDE5 inhibitors such as tadalafil despite the fact that both pathways can individually be therapeutically useful.
The disease and product context belongs on the tadalafil for pulmonary arterial hypertension page and the Adcirca product page.
| Drug / product | PAH-related context | Combination status |
|---|---|---|
| Tadalafil / Adcirca | PDE5 inhibitor used for PAH | Do not combine with riociguat |
| Riociguat / Adempas | sGC stimulator used in PAH and selected CTEPH contexts | Do not combine with tadalafil |
No. Cialis and Adcirca are different tadalafil brand contexts, but the interacting active drug is tadalafil. Riociguat labeling explicitly names tadalafil rather than limiting the contraindication to one brand.
That distinction matters because a patient or medication list may show tadalafil, Cialis, Adcirca or a generic tadalafil product. A different brand name does not remove the underlying PDE5 interaction.
Product identity should therefore be recognized at the active-ingredient level rather than by brand name alone.
| Product name | Active drug relevant to this interaction |
|---|---|
| Cialis | Tadalafil |
| Adcirca | Tadalafil |
| Generic tadalafil | Tadalafil |
| Interaction with riociguat | Contraindicated tadalafil/PDE5-inhibitor overlap |
Tadalafil has a mean terminal half-life of approximately 17.5 hours in healthy subjects, so its systemic exposure declines gradually rather than disappearing immediately after the final dose. This provides useful pharmacokinetic context for why the riociguat label specifies a longer pre-riociguat interval after tadalafil than after sildenafil.
However, the labeled transition interval should not be reconstructed by multiplying tadalafil's half-life or estimating when a personally chosen residual concentration seems low enough. The current riociguat label provides the transition instruction directly.
The meaning of the 17.5-hour PK value itself belongs on the tadalafil half-life page.
| Concept | Interpretation |
|---|---|
| Mean terminal tadalafil half-life | Approximately 17.5 hours in healthy subjects |
| Immediate disappearance after last dose | No |
| Useful for understanding persistence | Yes |
| Appropriate basis for inventing a personal transition interval | No |
The interaction is easy to oversimplify because both drugs affect cGMP signaling. They do not act through the same molecular target, riociguat is not a nitrate, and the contraindication is not based primarily on a change in tadalafil metabolism.
Another common error is to treat transition timing as evidence that planned concomitant treatment is acceptable. Current labeling instead separates clinician-managed switching from the prohibition on overlapping therapy.
Finally, clinical evidence involving sildenafil and riociguat should not be presented as if the same trial directly tested tadalafil.
| Misunderstanding | Correct interpretation |
|---|---|
| Riociguat is a nitrate | No; it is an sGC stimulator |
| Tadalafil and riociguat act on the same enzyme | No; tadalafil inhibits PDE5 while riociguat stimulates sGC |
| This is mainly a CYP3A4 interaction | No; it is primarily pharmacodynamic |
| A transition interval means overlap is allowed | No; concomitant use remains contraindicated |
| PATENT PLUS directly tested tadalafil + riociguat | No; the PDE5 inhibitor was sildenafil |
A medication review should identify tadalafil regardless of whether it appears as Cialis, Adcirca or a generic product. It should likewise recognize riociguat or Adempas as soluble guanylate cyclase stimulation rather than relying only on a brand name.
This matters especially when different specialists manage erectile dysfunction, BPH or pulmonary hypertension and the complete medication list may span more than one treatment context. The contraindication exists at the pharmacologic level even when the two prescriptions were written for different conditions.
Broader interaction screening remains the role of the tadalafil drug-interactions page.
| Medication-review check | Why it matters |
|---|---|
| Any tadalafil-containing product? | Identifies PDE5 inhibition relevant to the contraindication |
| Any riociguat / Adempas? | Identifies sGC stimulation |
| Different prescribers or indications? | Does not remove the interaction |
| Planned treatment transition? | Requires label-based clinician management rather than concomitant use |
Tadalafil and riociguat are contraindicated together under current U.S. labeling because tadalafil-mediated PDE5 inhibition can potentiate the hypotensive effects of soluble guanylate cyclase stimulation.
The drugs act at different molecular targets but converge on cGMP signaling: tadalafil reduces cGMP degradation, while riociguat sensitizes sGC to endogenous nitric oxide and directly stimulates sGC to increase cGMP production. Their overlap can therefore produce excessive vasodilation and blood-pressure lowering.
Current riociguat labeling also provides tadalafil-specific transition instructions, but these are clinician-directed switching rules rather than permission for concomitant therapy. PATENT PLUS adds relevant PDE5-class evidence but studied sildenafil, not tadalafil, so it should not be misrepresented as a direct tadalafil-riociguat trial.
No. Current U.S. tadalafil and riociguat labeling classifies concomitant tadalafil and riociguat use as contraindicated because PDE5 inhibition can potentiate the hypotensive effects of soluble guanylate cyclase stimulation.
Tadalafil inhibits PDE5 and reduces cGMP breakdown, while riociguat stimulates soluble guanylate cyclase and increases cGMP generation. Their overlapping effects can produce excessive vasodilation and clinically important hypotension.
Adempas is a U.S. brand of riociguat. Current Adempas labeling explicitly contraindicates concomitant administration with specific PDE5 inhibitors including tadalafil.
Yes. Current CIALIS labeling states not to use CIALIS in patients taking a guanylate cyclase stimulator such as riociguat because PDE5 inhibitors may potentiate the hypotensive effects of GC stimulators.
No. Riociguat is a soluble guanylate cyclase stimulator. Organic nitrates and riociguat both interact dangerously with tadalafil through cGMP-related vasodilation, but they are different drug classes with different mechanisms.
No. Tadalafil inhibits PDE5, an enzyme involved in cGMP degradation. Riociguat stimulates soluble guanylate cyclase, the enzyme that generates cGMP.
Current Adempas labeling describes two mechanisms: riociguat sensitizes soluble guanylate cyclase to endogenous nitric oxide and also directly stimulates soluble guanylate cyclase through a separate binding site independently of nitric oxide.
Not primarily. The contraindication is pharmacodynamic and reflects overlapping effects on cGMP signaling and blood pressure rather than one drug simply increasing the other's plasma concentration through CYP3A4 inhibition.
The concern is potentiated vasodilation and excessive blood-pressure lowering. Current tadalafil labeling warns that concomitant use with GC stimulators can cause blood pressure to fall to an unsafe level.
Riociguat patient information identifies symptoms of low blood pressure such as dizziness, lightheadedness and fainting. The contraindication is intended to prevent clinically significant overlap rather than wait for such symptoms to occur.
Yes. Current U.S. riociguat labeling states that tadalafil should be discontinued at least 48 hours before riociguat is administered. This is clinician-directed transition guidance and does not make concomitant tadalafil-riociguat therapy acceptable.
Current riociguat labeling states that riociguat should be discontinued at least 24 hours before a PDE5 inhibitor is administered, with monitoring for hypotension when the new therapy is initiated. This is a treatment-transition framework rather than permission for overlapping use.
The riociguat label specifies different intervals for the individual PDE5 inhibitors, including a longer interval after tadalafil. Tadalafil also has relatively long systemic persistence, but the labeled interval should be followed as written rather than recalculated from half-life.
Half-life helps explain tadalafil persistence but should not be used to invent a personal switching interval. Current riociguat labeling provides the tadalafil-specific transition instruction directly.
No. PATENT PLUS studied riociguat added to sildenafil in pulmonary arterial hypertension. It provides relevant PDE5-inhibitor class evidence but should not be described as a direct tadalafil-riociguat trial.
The study found no favorable clinical benefit from adding riociguat to sildenafil and identified unfavorable safety and tolerability signals during longer-term combination treatment, including frequent discontinuation related to hypotension. Those findings support the broader PDE5-inhibitor contraindication but are not tadalafil-specific event-rate data.
No. Adcirca contains tadalafil, and current tadalafil and riociguat labeling contraindicates concomitant tadalafil/PDE5-inhibitor use with riociguat.
No. The interacting active drug is tadalafil, not the indication or brand name. Riociguat labeling explicitly names tadalafil among contraindicated PDE5 inhibitors.
Tadalafil is used in PAH through products such as Adcirca, and riociguat is also labeled for PAH in appropriate patients. Their individual therapeutic roles do not make concomitant treatment acceptable; current labeling contraindicates the combination.
No. Both combinations are contraindicated and can produce excessive hypotension, but organic nitrates and riociguat act differently. Riociguat directly stimulates soluble guanylate cyclase and sensitizes it to nitric oxide, while nitrates act as nitric-oxide-related donors.